Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced that Saurabh Saha, MD, PhD, Chief Executive Officer and Gregory Weinhoff, MD, Chief Financial Officer, will participate in the following investor conferences:
Event: Jefferies Healthcare Conference
Date: Thursday, June 9, 2022
Fireside Chat Webcast Time: 4:30 PM ET
Event: Goldman Sachs 43rd Annual Global Healthcare Conference
Date: Wednesday, June 15, 2022
Fireside Chat Webcast Time: 8:00 AM PT/ 11:00 AM ET
Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at Events & Presentations | Centessa Pharmaceuticals.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc (“Centessa”) is a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications in rare diseases and immuno-oncology. We are led by a management team with extensive R&D experience, providing direct guidance to our program teams to rapidly advance our candidates from research through all stages of development. For more information, visit www.centessa.com, which does not form part of this release.
Contact:
Kristen K. Sheppard, Esq.
SVP of Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$12.87 |
Daily Change: | 0.25 1.98 |
Daily Volume: | 720,285 |
Market Cap: | US$1.700B |
May 14, 2025 March 24, 2025 November 12, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load